Oruka Therapeutics price target raised to $85 from $45 at Wedbush

1 month ago 23

Skip to navigation Skip to main contented Skip to close file

TipRanks

Thu, April 16, 2026 astatine 7:01 AM CDT 1 min read

Wedbush raised the firm’s price target connected Oruka Therapeutics (ORKA) to $85 from $45 and keeps an Outperform standing connected the shares. The steadfast reviewed anticipated benchmarks and banal setup for upcoming induction information from the Phase 2a EVERLAST-A proceedings of ORKA-001 for psoriasis. Wedbush speculates a information readout is apt successful May, and models a valuation of $4.77B for ORKA-001 successful a basal lawsuit script with PASI-100 rates of 35%-40%, accordant with different IL-23 mAbs successful psoriasis. Further, the steadfast anticipates tiered upside scenarios with PASI-100 efficacy thresholds of 40%-50%, 50%-60%, and implicit 60% yielding respective valuations of $5.56B, $6.35B, and $14.2B based connected expected marketplace stock increases and progressively accelerated proceedings timelines. Oruka remains 1 of Wedbush’s apical picks for 2026 and the steadfast sees country for sustained maturation adjacent from existent levels.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Discover top-performing banal ideas and upgrade to a portfolio of marketplace leaders with Smart Investor Picks

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected ORKA:

Disclaimer & DisclosureReport an Issue

Leerink sees Spyre’s SPY001 Phase 2 Data arsenic incrementally affirmative for Oruka
Oruka Therapeutics terms people raised to $78 from $73 astatine BTIG
Oruka Therapeutics terms people raised to $70 from $40 astatine H.C. Wainwright
Oruka Therapeutics terms people raised to $78 from $50 astatine Barclays
Oruka Therapeutics terms people raised to $75 from $50 astatine UBS

Read Entire Article